The preventive immunization Nous-209 works in an initial trial with patients who have 17 times the risk of developing tumors compared to the general population ...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an ...

Next-generation cancer tests are being developed here in Houston, and the HBJ pulled back the curtain on how one partnership ...

Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a ...

Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

OMI today announced the appointment of ChristopherWindham, MD, as ExecutiveChief Operating Officer and Chief Clinical Officer ...

Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update on January 7, 2026. With the appointment of Dr. Eileen ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...